Winslow Evans & Crocker Inc. decreased its position in C.R. Bard Inc. (NYSE:BCR) by 0.5% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 9,200 shares of the company’s stock after selling 50 shares during the period. Winslow Evans & Crocker Inc.’s holdings in C.R. Bard were worth $2,163,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Panagora Asset Management Inc. boosted its position in C.R. Bard by 3.5% in the first quarter. Panagora Asset Management Inc. now owns 499,651 shares of the company’s stock worth $101,264,000 after buying an additional 17,012 shares during the period. Squarepoint Ops LLC boosted its position in C.R. Bard by 49.4% in the first quarter. Squarepoint Ops LLC now owns 5,152 shares of the company’s stock worth $1,044,000 after buying an additional 1,703 shares during the period. Silvercrest Asset Management Group LLC boosted its position in C.R. Bard by 30.3% in the first quarter. Silvercrest Asset Management Group LLC now owns 6,026 shares of the company’s stock worth $1,221,000 after buying an additional 1,401 shares during the period. National Pension Service boosted its position in C.R. Bard by 4.5% in the first quarter. National Pension Service now owns 46,169 shares of the company’s stock worth $9,357,000 after buying an additional 1,998 shares during the period. Finally, UMB Bank N A MO boosted its position in C.R. Bard by 14.1% in the first quarter. UMB Bank N A MO now owns 2,594 shares of the company’s stock worth $526,000 after buying an additional 320 shares during the period. 87.95% of the stock is currently owned by institutional investors and hedge funds.

C.R. Bard Inc. (NYSE:BCR) traded up 1.17% on Friday, reaching $226.25. 749,665 shares of the company traded hands. The firm has a 50 day moving average price of $220.39 and a 200 day moving average price of $216.50. The stock has a market capitalization of $16.62 billion, a price-to-earnings ratio of 52.62 and a beta of 0.57. C.R. Bard Inc. has a 52-week low of $172.21 and a 52-week high of $239.43.

C.R. Bard (NYSE:BCR) last issued its quarterly earnings results on Tuesday, July 26th. The company reported $2.54 EPS for the quarter, topping analysts’ consensus estimates of $2.47 by $0.07. C.R. Bard had a return on equity of 48.43% and a net margin of 9.20%. The company earned $931.50 million during the quarter, compared to analyst estimates of $915.22 million. During the same period in the previous year, the company earned $2.27 earnings per share. The company’s quarterly revenue was up 8.3% compared to the same quarter last year. Equities research analysts predict that C.R. Bard Inc. will post $10.17 EPS for the current year.

A number of equities analysts have recently weighed in on BCR shares. Bank of America Corp. cut shares of C.R. Bard from a “buy” rating to a “neutral” rating in a research note on Friday, July 8th. Jefferies Group increased their price objective on shares of C.R. Bard from $215.00 to $237.00 and gave the company a “hold” rating in a research note on Wednesday, July 27th. Barclays PLC increased their price objective on shares of C.R. Bard from $212.00 to $224.00 and gave the company an “equal weight” rating in a research note on Tuesday, May 24th. JPMorgan Chase & Co. increased their price objective on shares of C.R. Bard from $214.00 to $225.00 and gave the company a “neutral” rating in a research note on Wednesday, July 27th. Finally, Leerink Swann reissued a “hold” rating on shares of C.R. Bard in a research note on Wednesday, May 25th. Thirteen investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $233.00.

In other news, VP John A. Deford sold 7,928 shares of the business’s stock in a transaction that occurred on Tuesday, September 6th. The stock was sold at an average price of $221.06, for a total transaction of $1,752,563.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.97% of the company’s stock.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.

5 Day Chart for NYSE:BCR

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard Inc. (NYSE:BCR).

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.